Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholder's Equity

v3.19.1
Consolidated Statements of Stockholder's Equity - USD ($)
$ in Thousands
Total
June 2018 Public Offering [Member]
October 2018 Registered Direct Offering [Member]
LPC [Member]
Common stock [Member]
Common stock [Member]
June 2018 Public Offering [Member]
Common stock [Member]
October 2018 Registered Direct Offering [Member]
Common stock [Member]
LPC [Member]
Preferred Stock [Member]
Preferred Stock [Member]
June 2018 Public Offering [Member]
Additional paid-in capital [Member]
Additional paid-in capital [Member]
June 2018 Public Offering [Member]
Additional paid-in capital [Member]
October 2018 Registered Direct Offering [Member]
Additional paid-in capital [Member]
LPC [Member]
Accumulated other comprehensive income (loss) [Member]
Accumulated deficit [Member]
Beginning Balance at Dec. 31, 2015 $ 1,840                   $ 2,667       $ 1 $ (828)
Beginning Balance, Shares at Dec. 31, 2015         2,123                      
Net loss (1,234)                             (1,234)
Other comprehensive income (loss) 4                           4  
Ending Balance at Dec. 31, 2016 610                   2,667       5 (2,062)
Ending Balance, Shares at Dec. 31, 2016         2,123                      
Stock-based compensation expense 348                   348          
Settlement of stockholder loans with related parties 2,132                   2,132          
Settlement of stockholder loans with related parties, Shares         157                      
Shares issued on subscription 64                   64          
Shares issued on subscription, Shares         5                      
Shares held by OncoGenex Shareholders 3       $ 3                      
Shares held by OncoGenex Shareholders, Shares         273,671                      
Shares issued on conversion of Achieve common shares $ 13,048       $ 8           13,040          
Shares issued on conversion of Achieve common shares, Shares         821,012                      
Shares cancelled on conversion of Achieve common shares         (2,285)                      
Restricted Stock Unit Settlements, Shares 546       546                      
Restricted Stock Unit Settlements withheld and retired to treasury $ (5)                             (5)
Restricted Stock Unit Settlements withheld and retired to treasury, Shares         (166)                      
Shares issued       $ 2,306       $ 1           $ 2,305    
Shares issued, Shares               99,730                
Purchase accounting adjustment (44)                             (44)
Net loss (10,583)                             (10,583)
Ending Balance at Dec. 31, 2017 7,879       $ 12           20,556       5 (12,694)
Ending Balance, Shares at Dec. 31, 2017         1,194,793                      
Stock-based compensation expense $ 854                   854          
Restricted Stock Unit Settlements, Shares 5,354       5,354                      
Adjustment of fractional shares on reverse stock split,shares         (38)                      
Shares issued   $ 12,194 $ 4,960 $ 1,279   $ 1 $ 2 $ 1       $ 12,193 $ 4,958 $ 1,278    
Shares issued, Shares           1,160,500 1,789,258 96,000   9,158            
Shares issued on exercise of warrants $ 1,324                   1,324          
Shares issued on exercise of warrants, Shares         330,500                      
Shares issued on conversion of preferred shares         $ 2           (2)          
Shares issued on conversion of preferred shares, Shares         2,144,750       (8,579)              
Net loss (12,687)                             (12,687)
Other comprehensive income (loss) (1)                           (1)  
Ending Balance at Dec. 31, 2018 $ 15,802       $ 18           $ 41,161       $ 4 $ (25,381)
Ending Balance, Shares at Dec. 31, 2018         6,721,117       579